Homoeostasis model assessment (HOMA) was used to estimate basal β-cell function (HOMA-B) and insulin resistance (HOMA-IR). HOMA-B was calculated as [20× fasting insulin (FINS)] / [fasting plasma glucose (FPG)—3.5]. HOMA-IR was calculated as FPG × FINS / 22.5 [14 (link)].
D 10 analyzer
The D-10 analyzer is a laboratory instrument designed for the analysis of hemoglobin variants and glycated hemoglobin (HbA1c) levels. It utilizes high-performance liquid chromatography (HPLC) technology to separate and quantify different hemoglobin fractions in a patient's blood sample.
Lab products found in correlation
19 protocols using d 10 analyzer
Metabolic Biomarkers in Fasting and Postprandial States
Homoeostasis model assessment (HOMA) was used to estimate basal β-cell function (HOMA-B) and insulin resistance (HOMA-IR). HOMA-B was calculated as [20× fasting insulin (FINS)] / [fasting plasma glucose (FPG)—3.5]. HOMA-IR was calculated as FPG × FINS / 22.5 [14 (link)].
Standardized Biomarker Assessment Protocol
Comprehensive Clinical Data and Metabolic Profiles
Induction of Diabetes in Mice
Biochemical Analyses in Clinical Research
Plasma Glucose and HbA1c Measurement Techniques
Contour® Next glucometer was used for CBG measurements (manufactured by Bayer HealthCare LLC). Fingertips were used for CBG sample using standard lancing device provided by the manufacturer. The test strips used flavin adenine dinucleotide-glucose dehydrogenase method for blood glucose testing.[8 (link)] The results of the glucometer are referenced to plasma/serum blood glucose values. The measuring range of the glucometer is 10–600 mg/dl.
Evaluating Laboratory Markers in T1D
Glucose, pH, and bicarbonate levels were determined using standard laboratory methods. HbA1c was evaluated from whole blood using an HPLC method (D-10 analyzer, Bio-Rad, Hercules, CA, USA). Fasting serum C-peptide levels were determined using the electrochemiluminescence immunoassay method (Cobas e411, Roche Diagnostic, Basel, Switzerland). Pancreatic autoantibodies (against glutamic acid decarboxylase, tyrosine phosphatase, and insulin were detected using commercial ELISA kits (RSR Ltd., Cardiff, UK), according to the manufacturer’s instructions. Mean HbA1c was calculated using all obtained values during the first year of the follow-up. Delta HbA1c was calculated as a difference in HbA1c values at the time of T1D diagnosis and after one year of T1D duration. HbA1c values were transformed to the International Federation of Clinical Chemistry values (
Evaluating Glycemic Control through HbA1c and eAG
The random blood glucose and HbA1c levels of 461 patient samples (178 male and 283 female) were included in the study. Blood samples were taken on the same day for the determination of both RBS and HbA1c. The eAG levels (mg/dL) were calculated using the following formula: 28.7 × HbA1c – 46.7. The samples were divided into four groups on the basis of HbA1c levels as group 1: HbA1c greater than 9% (poorly controlled diabetic), group 2: HbA1c 6.5 to 9% (fairly controlled diabetic), group 3: HbA1c 5.7 to 6.4% (prediabetic), and group 4: HbA1c less than 5.7% (nondiabetic).
8 (link)
Glucose levels were determined using the glucose oxidase method in Transasia Erba analyzer with commercially available Agappe kits. HbA1c levels were determined using high-performance liquid chromatographic method on Biorad D10 analyzer with Biorad kits.
Biochemical and Lipid Profile Analysis
The atherogenic indices were calculated as follows:
[13] (link)
[14] (link)
[15] (link)
[16] (link)
Comprehensive Metabolic and Renal Assessment
The serum lipid content (TG, TC, and HDL) was determined using commercial kits (BioSystems, Spain) and a biochemical analyzer (Synchron SH9 Pro, Beckman Coulter, Brea, CA, USA). The levels of LDL were calculated using the Friedewald formula [34 (link)]: LDL = TC − (HDL + VLDL)). The level of VLDL equaled TG/2.2.
Methods used for kidney damage determination in the early studies included a GFR calculation, urinary albumin and ratio of albumin/creatinine. These were determined on a biochemical analyzer (Synchron SH9 Pro, Beckman Coulter, Brea, CA, USA) using the immunoturbidimetric method. The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula was used for calculating GFR (mL/min/1.73 m2).
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!